InsiderTape plots every Form 4 on the price chart and flags cluster buys, CEO conviction, and first buys in years the moment they file. Start a free 7-day trial, cancel anytime.
START FREE TRIAL →Eric Easom, Chief Executive Officer, is a corporate insider tracked by InsiderTape across 1 company. The public record shows 20 open-market SEC Form 4 transactions: 3 purchases worth $115K and 17 sales worth $1.4M, reported from Oct 20, 22 to Jun 2, 25. Over this period they have been a net seller.
| Date | Company | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 2, 25 | ANTXAN2 Therapeutics, Inc. | BUY | 10.0K | $1.07 | $11K |
| Nov 18, 24 | ANTXAN2 Therapeutics, Inc. | BUY | 50.0K | $1.00 | $50K |
| Jan 2, 24 | ANTXAN2 Therapeutics, Inc. | SELL | 2.8K | $20.09 | $56K |
| May 15, 23 | ANTXAN2 Therapeutics, Inc. | BUY | 10.0K | $5.38 | $54K |
| Nov 14, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 23 | $15.04 | $346 |
| Nov 10, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 4.4K | $15.32 | $68K |
| Nov 9, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 10.1K | $15.61 | $158K |
| Nov 8, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 5.8K | $16.38 | $89K |
| Nov 7, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 10.2K | $16.72 | $162K |
| Nov 4, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 8.8K | $15.80 | $139K |
| Nov 3, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 11.1K | $16.02 | $174K |
| Nov 2, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 1.5K | $15.07 | $23K |
| Oct 31, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 2.7K | $15.39 | $41K |
| Oct 28, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 1.7K | $15.09 | $25K |
| Oct 27, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 924 | $15.36 | $14K |
| Oct 26, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 1.7K | $15.10 | $25K |
| Oct 25, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 4.3K | $16.20 | $67K |
| Oct 24, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 2.9K | $16.17 | $46K |
| Oct 21, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 11.6K | $16.69 | $189K |
| Oct 20, 22 | ANTXAN2 Therapeutics, Inc. | SELL | 7.3K | $17.15 | $121K |